3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Completed
73
Terminated
33
Recruiting
20
Active not recruiting
14
Unknown
10
Withdrawn
8
Suspended
1
Not yet recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Myeloid
1
Conditions
Leukemia, Myeloid, Acute
24
Leukemia
3
Recurrence
1
Myeloproliferative Disorders
1
Myelodysplastic Syndromes
1
Lymphoma, T-Cell, Peripheral
1
Lymphoma, Large B-Cell, Diffuse
1
Lymphoma, Extranodal NK-T-Cell
1
Leukemia, Myeloid
1
Leukemia, Lymphocytic, Chronic, B-Cell
1
Higher-risk Myelodysplastic Syndrome
1
Hematologic Diseases
1
Dendritic Cell Sarcoma, Interdigitating
1
Bone Marrow Diseases
1
Interventions
Tacrolimus
2
Specimen Handling
2
Lymphatic Irradiation
2
Biopsy
2
venetoclax
1
selinexor
1
olutasidenib
1
fludarabine phosphate
1
fludarabine
1
decitabine and cedazuridine drug combination
1
Thiotepa
1
Sirolimus
1
Receptors, Antigen, T-Cell
1
Quality of Life
1
Peripheral Blood Stem Cell Transplantation
1
Melphalan
1
Maintenance
1
Levofloxacin
1
Idarubicin
1
Fibroblast Growth Factor 7
1
Electrocardiography
1
Cytarabine
1
Clinical Laboratory Techniques
1
Busulfan
1
Bone Marrow Examination
1
Blood Specimen Collection
1
Azacitidine
1
11-(2-pyrrolidin-1-ylethoxy)-14,19-dioxa-5,7,26-triazatetracyclo(19.3.1.1(2,6).1(8,12))heptacosa-1(25),2(26),3,5,8,10,12(27),16,21,23-decaene
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Not yet recruiting
×
Myelodysplastic Syndromes
×
Azacitidine
×
Clear all
NCT07387354
2026-03-16
MDS
Thomas Jefferson University
Phase 1/2
Not yet recruiting
25 enrolled